BPC May 23 updates: EXEL release Phase 2 RCC data + NVCR VTL trial updates

May 23, 2016 No Comments by

Updates to the Company Pipeline Database for May 23, 2016, are as follows. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Summary EXEL 6.00 Cabozantinib – CABOSUN Cancer – First-Line RCC Phase 2 Phase 2 data released May 2016 – enpoint met NVCR 11.52 Tumor Treating Fields (TTFields) – PANOVA Pancreatic cancer Phase 2 […]

Daily News Read more

ORMP Phase 2b diabetes data due in around two weeks + updates from reporting companies ARQL ESPR EXEL INFI LOXO MGNX NVAX ONCE OPHT VNDA XOMA

May 05, 2016 No Comments by

Updates to the Company Pipeline Database for May 4, 2016, are as follows. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Summary ORMP 9.50 ORMD-0801 Type 2 Diabetes Phase 2 Phase 2 top-line data due around May 18 2016 – noted on May 4 that data will be released in around 2 weeks ESPR […]

Daily News Read more

Advisory Committee votes against SRPT eteplirsen. EXEL receives FDA Approval for RCC + BPMX TTHI updates

Apr 25, 2016 No Comments by

Updates to the Company Pipeline Database for April 25, 2016 are as follows. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Summary BPMX 0.93 BPX-01 Acne Phase 2 Phase 2a enrolment completed April 2016. Trial expected to end by mid 2016 EXEL 4.66 CABOMETYX (cabozantinib) Cancer – metastatic renal cell cancer (RCC) Approved Approved […]

Daily News Read more

ALDX release positive data. EGLT PDUFA date set. HRTX PDUFA delay + updates for ALDX ARQL CHRS CMRX CRIS DERM DRRX EXEL FGEN FOLD GLYC HALO KITE MGNX NLNK NVAX NVLS ONTY OPK PBYI PTCT PTLA SPPI

Mar 01, 2016 No Comments

Updates to the Company Pipeline Database for February 29, 2016 are as follows. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Summary ALDX 4.90 NS2 Allergic conjunctivitis Phase 2 Phase 2 postive data released late February 2016 ALDX 4.90 NS2 Noninfectious anterior uveitis Phase 2 Phase 2 data due 2Q 2016 ARQL 1.89 Tivantinib […]

Read more

EXEL PDUFA date set for June 22. RIGL Phase 3 data due mid year + updates for CORT NBIX

Jan 29, 2016 No Comments

Updates to the Company Pipeline Database for January 28, 2016 are as follows. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Summary CORT 3.28 Mifepristone in combination with eribulin Cancer – triple-negative breast cancer Phase 1/2 Phase 1/2 data due mid 2016 CORT 3.28 CORT125134 Cushing’s syndrome Phase 2 Phase 2 trial to be […]

Read more

Latest updates for INCY PCYC SGEN BMRN CEMP CYTK CYTR EBIO EXEL KYTH LPCN LXRX MDCO NBIX NBS OCRX OGXI OPK THLD THRX TSRO

May 02, 2015 No Comments

Latest updates to the Company Pipeline Database for April 29-May 1 2015. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Summary INCY 98.28 Ruxolitinib – JANUS 1 and JANUS 2 Cancer – Pancreatic Phase 3 Phase 3 data for JANUS 1 due 2016. JANUS 2 due at a later date PCYC 254.51 IMBRUVICA […]

Read more

SHPG PDUFA date set. EXEL data due 2H 2015. DERM initiates Phase 2 acne trial.

Apr 10, 2015 No Comments

Latest updates to the Company Pipeline Database for April 9. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Summary DERM 15.15 DRM01 Acne Phase 2b Phase 2b initiated April 2015. Data due 1H 2016 EXEL 3.01 Cabozantinib – (METEOR) Cancer – metastatic renal cell cancer (RCC) Phase 3 Data due 2Q 2015 […]

Read more

Pipeline updates for ALKS ARDX ATRS BMRN CEMP CLDX CLVS DPRX DYAX EXEL FLXN INFI NKTR TBPH XOMA

Feb 26, 2015 No Comments

Latest updates to the Company Pipeline Database for February 24-25, 2015. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Link Text Updated ALKS 71.11 ALKS 5461 Major depressive disorder Phase 2 Phase 3 (two trials) initiated Jun 2014. Data due 2016. Third Phase 3 trial initiated mid 2014. Data due […]

Read more

Updates for week ending February 20

Feb 20, 2015 No Comments

Latest updates to the Company Pipeline Database for week ending February 20, 2015. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Link Text Updated AGIO 106.30 AG-348 Pyruvate kinase deficiency Phase 2 Phase 2 trial to be initiated 1H 2015 2/21/2015 ARIA 8.06 Brigatinib – ALTA trial Anaplastic lymphoma kinase […]

Read more

Pipeline updates for ACOR BLRX EXEL RARE SPHS LPCN VBLT ZFGN

Dec 16, 2014 No Comments

Latest updates to the Company Pipeline Database from December 15 2014. Refer to the FDA Calendar for upcoming catalysts Ticker Price Drug Indication Stage Link Text Updated ACOR 38.4 Dalfampridine Post stroke deficits Phase 2b/3 Annonuced Dec 15, 2015 that a Phase 3 trial has been initiated 12/16/2014 BLRX 1.63 BL-8040 Cancer – Acute myeloid leukemia […]

Read more

EXEL fails Phase 3 COMET-2 trial + updates for CANF FLXN GLMD QURE NKTR

Dec 02, 2014 No Comments

Latest updates to the Company Pipeline Database from December 1 2014: Ticker Price Drug Indication Stage Notes Updated CANF 4.45 CF101 Psoriasis Phase 2/3 Phase 2/3 topline data due 1Q 2015 12/2/2014 CANF 4.45 CF101 Rheumatoid arthritis Phase 3 Phase 3 planned 12/2/2014 CANF 4.45 CF101 Glaucoma Phase 2 Phase 2 data due 2Q or […]

Read more